Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

BioMarin

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.

Astellas, Catalyst approvals set up record year for FDA approvals

Astellas, Catalyst approvals set up record year for FDA approvals

The drug was originally developed by BioMarin, which got EU approval in 2009 and licensed it to Catalyst three years later.

BioMarin eyes 2019 FDA filing for haemophilia A gene therapy

BioMarin eyes 2019 FDA filing for haemophilia A gene therapy Valrox phase 1/2 data conforms to regulatory requirements for expedited registration,” said Geoff Nichol, BioMarin’s chief medical officer, during the update. ... our development and accelerated regulatory strategy,” said BioMarin’s chief

Bayer roll-out of haemophilia drug Jivi gathers pace

Bayer roll-out of haemophilia drug Jivi gathers pace BioMarin and Spark Therapeutics.

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy them.”. Another variant of the disease, MPS IVa already has a treatment available – Biomarin’s Vimizim.

Spark sputters on haemophilia A gene therapy safety scare

Spark sputters on haemophilia A gene therapy safety scare Investors compare data unfavourably with BioMarin rival. Gene therapy developer Spark Therapeutics has seen around $1bn carved off its value after it emerged that two patients in its haemophilia A gene ... meeting the factor threshold because of

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics